-
Mashup Score: 0Enfortumab Vedotin Shows Durable Responses in Pivotal Phase 2 Study of Advanced Urothelial Cancer - 4 year(s) ago
Enfortumab vedotin-ejfv induced durable responses as treatment of patients with locally advanced or metastatic urothelial cancer who have previously received immunotherapy but not a prior platinum-containing chemotherapy and are not eligible for cisplatin.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Enfortumab vedotin-ejfv induced durable responses in patients with locally advanced or metastatic urothelial cancer who have previously received immunotherapy but not a prior platinum-containing chemo/are not eligible for cisplatin. https://t.co/hnXP6ymunO #blcsm #blcaddercancer